Virginia Retirement Systems’s BioCryst Pharmaceuticals BCRX Stock Holding History

Virginia Retirement Systems’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$438K	Sell	43,754 -169,500	-79%	-$1.53M	﹤0.01%	1007
2026 Q1	$2.03M	Sell	213,254 -20,100	-9%	-$156K	0.02%	434
2025 Q4	$1.82M	Buy	233,354 +120,350	+107%	+$870K	0.01%	443
2025 Q3	$858K	Buy	113,004 +29,300	+35%	+$244K	0.01%	637
2025 Q2	$750K	Buy	83,704 +27,000	+48%	+$251K	0.01%	652
2025 Q1	$425K	Buy	+56,704	New	+$457K	﹤0.01%	798
2023 Q3	$333K	Sell	47,100 -33,500	-42%	-$241K	﹤0.01%	789
2023 Q2	$567K	Buy	80,600 +64,900	+413%	+$521K	0.01%	695
2023 Q1	$131K	Buy	15,700 +4,500	+40%	+$43.3K	﹤0.01%	990
2022 Q4	$129K	Buy	+11,200	New	+$140K	﹤0.01%	1083
2021 Q1	–	Sell	-10,500	Closed	-$78K	–	1105
2020 Q4	$78K	Hold	10,500	–	–	﹤0.01%	1090
2020 Q3	$36K	Sell	10,500 -4,400	-30%	-$18.9K	﹤0.01%	1071
2020 Q2	$71K	Buy	+14,900	New	+$59.5K	﹤0.01%	1071
2020 Q1	–	Sell	-16,900	Closed	-$58K	–	1091
2019 Q4	$58K	Buy	+16,900	New	+$42.5K	﹤0.01%	1118

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Jupiter Topco New York $245B AUM

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Virginia Retirement Systems's BCRX Position: Q2 2026 in Review

Virginia Retirement Systems reduced its BioCryst Pharmaceuticals (BCRX) stake by 79% in Q2 2026, selling an estimated $1.53M and leaving 43,754 shares worth $438K. The position accounts for ﹤0.01% of the portfolio, ranked #1007.

Virginia Retirement Systems first reported a position in BCRX in Q4 2019 and has held it in 14 quarters since. The position peaked at $2.03M in Q1 2026. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

Virginia Retirement Systems held 43,754 shares of BioCryst Pharmaceuticals worth $438K as of Q2 2026.
Virginia Retirement Systems sold 169,500 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $1.53M.
BioCryst Pharmaceuticals made up ﹤0.01% of Virginia Retirement Systems's portfolio in Q2 2026, its #1007 holding.
Virginia Retirement Systems first reported a position in BioCryst Pharmaceuticals in Q4 2019 and has held it in 14 quarters since.
Virginia Retirement Systems's BioCryst Pharmaceuticals position peaked at $2.03M in Q1 2026.
318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Virginia Retirement Systems's 13F filing for Q2 2026, filed 25 Aug 2026.